REG - Trellus Health PLC - Contract signed with second leading CRO

Trellus HealthAnnouncement

07/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251107:nRSG5733Ga&default-theme=true

RNS Number : 5733G  Trellus Health PLC  07 November 2025

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Contract signed with second leading CRO

 

LONDON, U.K. AND NEW YORK, U.S. (07 November 2025). Trellus Health® plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programs and value-based solutions to manage complex chronic
conditions, announces it has signed a 12 month contract (the "Contract") with
one of the largest global clinical research organisations ('CRO's') to utilise
its Trellus TrialSet™ offering. The Contract is due to commence before year
end, and will focus on immunology and inflammation, supporting recruitment and
enrolment optimisation for two late-stage clinical trials.

 

This marks the Company's second contract with a leading CRO, further
reinforcing the clinical trials sector as a strategic growth area for Trellus
Health(®). The Trellus TrialSet™ program is designed to enhance clinical
trial recruitment by identifying individuals with lower resilience who may be
hesitant to enrol and providing structured, evidence-based support to
strengthen their resilience and readiness for participation.

 

The Contract, which includes an upfront fee, a monthly management fee, and
milestone payments, is structured around three key performance indicators: (i)
the number of potential eligible participants opting into the Trellus
TrialSet™ program, (ii) the increase in qualified participants referred for
screening, and (iii) the reduction in the screen failure rate.

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "This
represents another important milestone for Trellus Health®, underscoring the
intrinsic value of our Trellus TrialSet™ digital solution and reflecting our
continued focus on strategic execution. Since its launch earlier this summer,
we have entered into two agreements with leading CROs, validating the
relevance and differentiation of our offering. While the contract does not
immediately extend the Company's current cash runway beyond early December
2025, combined with the Patient Support Program agreement signed with Johnson
& Johnson in January 2025 which launched in the spring, these milestones
demonstrate the growing recognition of the value Trellus Health delivers to
the pharmaceutical sector.

 

"The Company continues to explore options for a potential equity
fundraising and further updates will be provided in due course, as
appropriate."

 

Regulatory Information

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the
Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication
of this announcement, this inside information is now considered to be in the
public domain.

 

Enquiries:

 

 Trellus Health plc                                                     https://trellushealth.com/ (https://trellushealth.com/)

 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder            Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets
 Jen Boorer / James Todd / Patrick Weaver                              Tel: +44 (0)20 7496 3000

 Walbrook PR           Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                       (mailto:trellus@walbrookpr.com)
 Paul McManus / Lianne Applegarth /          Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
 Alice Woodings                                                        +44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted
in over 90% fewer hospitalisations and a reduction of over 70% in emergency
room visits. Given the common emotional and mental health struggles associated
with a variety of chronic conditions and therapeutic areas, Trellus Health®
considers its approach to have potential utility and demand across many
conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical
partners spanning clinical trials to commercialisation, applying the same
validated resilience science and platform to support trial success and
long-term patient engagement

 

The Company was founded by Icahn School of Medicine at Mount Sinai faculty
members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading
experts in treating both the physical and emotional impacts of IBD, with a
combined 50 years of pioneering whole-person healthcare innovation.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUPGWWGUPAGMQ



            Copyright 2019 Regulatory News Service, all rights reserved